Tafluprost met primary endpoint in phase III study, showing comparable IOP-lowering effect to timolol. The medication achieved significant IOP reduction from baseline and demonstrated non-inferiority to existing treatments.
Weill Cornell Medical College in Qatar offers a six-year pre-medical and medical curriculum with technology-driven innovations, providing international students with an American M.D. degree. The program is designed for the region, with high academic standards and admission requirements similar to those at Cornell University.
Benicar-based treatment algorithms significantly reduced mean systolic blood pressure in Stage 2 hypertensive populations. In Stage 1 patients, 89% reached the aggressive blood pressure goal of less than 130/85 mmHg.
Researchers found that taking Welchol, a bile acid sequestrant, with TriCor, a fibrate, resulted in no significant interaction. The study involved 30 healthy volunteers who received different treatment regimens involving the two drugs, showing that co-administration is safe and effective.
The study found that BENICAR and Benicar HCT helped patients reach aggressive blood pressure goals, with nearly 69.3% achieving less than or equal to 130/85 mmHg after 16 weeks. Additionally, BENICAR was found to be more effective in reaching blood pressure goals compared to other ARBs like Cozaar and Diovan.
A scientific working group found that renaming premature ejaculation could lead to confusion and require re-education. Instead, they recommend using the current term to describe the condition, which is associated with stigma rather than the name itself. The group also emphasizes the importance of open dialogue about male sexual health.
A statistical model predicts rapid increase in spinal fractures over time if left untreated, highlighting the importance of intervention before first fracture occurs. The study emphasizes the need for therapy that reduces risk of first fracture within one year to substantially reduce future fracture risk.
A randomized, double-blind trial involving 1,484 couples found that Valtrex reduced symptomatic genital herpes transmission by 75% and overall acquisition by 48%. The study showed consistent results with previous studies on recurrences.
A new study found that Actonel maintained the size of calcium-based mineral crystals and the integrity of collagen structure over five years, preserving bone quality. This is significant because osteoporosis therapies should aim to reduce fracture risk, not just treat symptoms.
A study analyzing data from pivotal trials of Actonel revealed that bone mineral density explains only a small portion of nonvertebral fracture risk reduction. The analysis found that BMD increases accounted for just 12.2% of the fracture risk reduction at lumbar spine, and 5.5% at femoral neck.
A 7-year study shows Actonel significantly reduces vertebral fracture incidence, with annualized rates of 4.7%, 5.2%, and 3.8% for the treatment group, respectively. Adverse events were similar to those in patients taking placebo during the first 5 years.
A recent study evaluated the medical costs of osteoporosis therapies and found that patients taking weekly Fosamax had lower GI-related medical costs compared to those taking daily or weekly doses. The analysis, conducted with a large medical claims database, also revealed that treating patients with a weekly dose of Fosamax versus a d...
The study found that the GlucoWatch Biographer improved diabetes control in children by detecting hypoglycemia more frequently and reducing average HbA1c levels. The device was well-tolerated, with only one subject experiencing a mild skin reaction.
Actonel significantly reduced fracture risk in high-risk postmenopausal women, with a 62% reduction seen at one year. The medication was found to be effective in reducing spinal fractures in patients over 70 years old and those with low hip BMD.
Postmenopausal women taking glucocorticoids are at a significantly increased risk of spinal fractures, with nearly six-fold higher odds compared to those not using the medication. Long-term use for chronic diseases can lead to glucocorticoid-induced osteoporosis (GIO), which increases the risk of fracture.
A study projects that increasing BMD testing for women with osteoporosis or osteopenia would reduce fractures by 6,683 over three years and result in net Medicare savings of $15.5 million. This could lead to increased patient benefits while reducing costs.
Researchers analyzed historical placebo control data with Actonel treatment for osteoporosis, revealing a significant reduction in new vertebral fractures. The study found that once-week treatment with Actonel reduced the risk of new vertebral fractures by 77% at one year.
A new analysis shows that Actonel reduced the risk of nonvertebral osteoporotic fractures by 74 percent within one year in postmenopausal women with osteoporosis. The effect was observed as early as six months, and the study included 1172 patients who received either placebo or Actonel 5 mg daily.
A new analysis reveals that early intervention with Actonel significantly reduces the risk of first vertebral fractures in postmenopausal women. The study found a 75% decrease in fracture risk among women treated with Actonel, compared to those on placebo.
The FDA has approved Actonel 35 mg once-a-week for the treatment and prevention of postmenopausal osteoporosis, showing a significant increase in lumbar spine bone mineral density at 12 months. The study found that once-a-week dosing is therapeutically equivalent to daily dosing.
A first-of-its-kind clinical study presented at the AAGP meeting shows that treatment with ARICEPT significantly improved cognitive and global function in patients with vascular dementia. The study, which included 616 patients, found improvements in both cognitive abilities and overall functioning.
Scientists have identified the PKHD1 gene as the cause of autosomal recessive polycystic kidney disease (ARPKD), a life-threatening genetic disorder. The discovery provides a genetic roadmap for understanding how the disease progresses, paving the way for more accurate diagnoses and treatments.
A new study found that Actonel 35mg taken once a week was equally effective to 5mg daily in improving bone density in postmenopausal women. The treatment also showed a comparable adverse event profile. This alternative dosing regimen may be beneficial for some patients and physicians.
A study presented at the American College of Gastroenterology meeting found that Actonel 5mg daily significantly reduced vertebral fracture risk by 70% in patients on chronic glucocorticoid therapy. Patients who received calcium supplementation and vitamin D also experienced significant reductions in bone loss.
New findings show that Actonel therapy can reduce clinical vertebral fractures in postmenopausal women as early as six months. The data suggests that treatment with Actonel can stop the fracture cascade and improve bone health.
A retrospective analysis found that Risedronate reduced nonvertebral fracture risk by 69% at six months, compared to a 54% reduction in risk for patients taking Alendronate. This study suggests that Risedronate is an effective treatment option for osteoporosis prevention and treatment.